Pediatrix Medical Group, Inc. — Q2 2023 Form 10-Q
Business context and period. Pediatrix provides physician services focused on newborn, maternal-fetal, pediatric and other subspecialty care, with affiliated physicians operating in 37 states. This unaudited quarterly filing covers the three and six months ended June 30, 2023; comparisons are to the corresponding 2022 periods. Amounts below are in millions of dollars unless noted.
Financial performance and position
- Q2 revenue: $500.6, up 3.0% from $486.0. Net patient service revenue was $430.4 and hospital contract administrative fees were $69.6.
- Q2 earnings: Operating income was $48.5, down 3.3%; operating margin was 9.7% versus 10.3%. Continuing-operations income was $28.3 versus $30.7. Net income was $28.3 versus $27.1, and diluted EPS was $0.34 versus $0.32. Adjusted EBITDA was $59.1 versus $65.6; adjusted EPS was $0.39 versus $0.47.
- First-half revenue and earnings: Revenue was $991.6, up 2.4%. Operating income was $78.5 versus $89.3, and operating margin was 7.9% versus 9.2%. Continuing-operations income was $42.5 versus $9.8; net income was $42.5 versus $5.9, and diluted EPS was $0.52 versus $0.07. Adjusted EBITDA was $99.2 versus $116.2; adjusted EPS was $0.62 versus $0.79.
- Costs and drivers: Q2 practice salaries and benefits rose 7.0% to $354.0, faster than revenue; practice supplies and other operating expenses rose 4.1% to $31.1. G&A fell to $58.0 from $61.2 and declined to 11.6% of revenue from 12.6%. No transformational or restructuring expense was recorded in Q2 2023, compared with $5.3 in Q2 2022.
- Cash flow and liquidity: First-half cash used in operating activities from continuing operations was $8.0, versus $8.3; cash used in investing was $21.7, and financing provided $29.6. Cash and equivalents were $5.8 at June 30, with $98.5 of short-term investments. Working capital was $77.4, versus $1.0 at year-end 2022, primarily reflecting increased line-of-credit borrowings. DSO improved to 49.2 days from 53.1 at year-end and 58.2 a year earlier.
- Debt: At June 30, principal outstanding was $400.0 on 5.375% senior notes due 2030 and $275.4 under the credit agreement ($234.4 term loan and $41.0 revolver). The company reported $409.0 available under the credit agreement. The facility matures in 2027 and includes financial covenants; management said the company was in material compliance and expected to remain compliant through 2023.
Material changes versus prior periods
- Q2 same-unit revenue rose 3.2%, reflecting reimbursement-related gains of 2.6% and volume growth of 0.6%. Higher maternal-fetal medicine and neonatology volumes were partly offset by declines in other hospital-based pediatric subspecialties.
- Management attributed Q2 margin and adjusted-earnings pressure mainly to higher clinical compensation, benefits and other operating costs. Improved cash collections and higher hospital administrative fees supported revenue; G&A savings partly offset cost increases.
- First-half operating margin and Adjusted EBITDA declined despite revenue growth, reflecting higher operating expenses, lower CARES Act relief and unfavorable non-same-unit results. Same-unit revenue increased 2.3%, including 0.8% volume growth.
- The much higher first-half 2023 GAAP income versus 2022 is materially affected by the prior-year $57.0 debt-extinguishment loss and $3.8 loss from discontinued operations. The 2022 first-half Adjusted EBITDA and adjusted EPS comparisons also exclude the debt-extinguishment loss under the company’s non-GAAP definitions.
Outlook, risks and unusual items
- No numerical earnings or revenue guidance is provided. Management expects operating funds, cash and available credit to cover working capital, anticipated acquisitions and capital expenditures, restructuring costs, repurchases and contractual obligations for at least 12 months from the filing date.
- Risks include reimbursement and payor-mix shifts toward lower-paying government programs, patient inability to pay, healthcare policy changes, and the No Surprises Act and related independent dispute resolution process. Management said the effects of the law and evolving rules remain uncertain.
- Professional liability exposure is significant: total professional liability reserves were $292.8, including $29.0 classified as current; a $47.0 insurance receivable was recorded for certain covered claims. The company self-insures a portion of this exposure and cautions coverage may not be adequate for all claims.
- Government audits, inquiries and investigations are expected in the ordinary course; no accrual was recorded for these matters because potential liabilities could not be reasonably estimated. The company also faces ordinary-course malpractice and other litigation; outcomes are uncertain.
- A 1% change in interest rates on the credit-agreement balance would affect annual pretax income by approximately $2.8. Management reported no material change in previously disclosed risk factors. Disclosure controls were assessed as effective.
- After quarter-end, on July 31, 2023, the board amended the bylaws to shorten the notice required for special board meetings from 48 hours to 24 hours.
Important facts for investors to verify
- Whether revenue growth and improved collections persist, and how reimbursement, payor mix and No Surprises Act dispute outcomes affect realized rates.
- Whether salary, incentive compensation and other practice-cost growth moderates enough to stabilize operating margins and Adjusted EBITDA.
- Cash conversion and working-capital trends, including the timing of incentive-compensation payments and continued DSO improvement.
- Debt balances, variable-rate exposure, covenant headroom and availability under the revolver; distinguish principal debt from balance-sheet carrying amounts and lease liabilities.
- Development of professional liability claims, insurance recoveries, government reviews and litigation, including any changes to estimates or coverage.
- Comparability of non-GAAP Adjusted EBITDA and Adjusted EPS with GAAP results, and the effect of prior-period debt and discontinued-operation items.